Lakefront Biotherapeutics (LKFT) Short-term Investments (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Short-term Investments for 13 consecutive years, with $3.3 billion the latest figure, recorded in Q1 2026.

• Quarterly Short-term Investments fell 8.59% year-over-year to $3.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 billion (down 8.59% YoY) and the FY2025 annual result came in at $3.4 billion, down 9.64% from the prior year.
• Short-term Investments held at $3.3 billion in Q1 2026 per LKFT's latest filing, from $3.3 billion in the prior quarter.
• Over the last five years, Short-term Investments for LKFT reached as high as $4.4 billion in Q1 2023 and fell as low as -$2.9 billion in Q3 2022.
• A 5-year average of $2.9 billion and a median of $3.6 billion in 2025 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2022 — Short-term Investments tumbled 47.67% — and 2025, when it jumped 14217.32%.
• Year by year, Short-term Investments stood at $1.5 billion in 2022, then jumped by 172.16% to $4.0 billion in 2023, then declined by 13.2% to $3.5 billion in 2024, then slipped by 4.69% to $3.3 billion in 2025, then advanced by 0.18% to $3.3 billion in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $3.3 billion, $3.3 billion, and $3.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.